Skip to main content

Rhabdomyolysis and/or Creatine Kinase Laboratory Results Following New Use of Statins or Angiotensin-Converting Enzyme Inhibitors

Basic Details
Date Posted
Status
Complete
Medical Product
angiotensin-converting enzyme (ACE) inhibitor
statin
Health Outcome(s)
creatine kinase laboratory result
rhabdomyolysis
Description

These reports contain the estimated rates of inpatient rhabdomyolysis and/or creatine kinase (CK) laboratory results following new use of statins or angiotensin-converting enzyme (ACE) inhibitors. Data from January 1, 2006 to December 31, 2015 from 11 Data Partners contributing to the Sentinel Distributed Database (SDD) were included in this report. This request was distributed on February 19, 2016.

Deliverables (2)
Sentinel Modular Program Report: Rhabdomyolysis and/or Creatine Kinase Laboratory Results Following New Use of Statins or Angiotensin-Converting Enzyme Inhibitors, Report 1 Sentinel Modular Program Report: Rhabdomyolysis and/or Creatine Kinase Laboratory Results Following New Use of Statins or Angiotensin-Converting Enzyme Inhibitors, Report 2
Additional Details
FDA Center
CDER
Time Period
January 1, 2006 - December 31, 2015
Analysis Type
Descriptive
Population / Cohort
Individuals 22 years of age and older
Data Sources
Sentinel Distributed Database (SDD)